Monia Guidi

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


93 publications

Sous presse | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2009 | 2007 |
Sous presse
 
Importance of Sex-Dependent Differences for Dosing Selection and Optimization of Chemotherapeutic Drugs.
Seydoux C., Briki M., Wagner A.D., Choong E., Guidi M., Carrara S., Thoma Y., Livio F., Girardin F.R., Marzolini C. et al. Chemotherapy. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_84F759610A36]
 
Is Non-Sustained Viral Suppression with Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug levels?
Thoueille P., Marzolini C., Guidi M., Cavassini M., Decosterd L.A. Clinical infectious diseases. Peer-reviewed.
[DOI][Pmid][serval:BIB_3FF55B9C536F]
2025
 
Population pharmacokinetic modelling of cetirizine concentrations in human breast milk-A contribution from the ConcePTION project.
Melander E., Nielsen E.I., Lindqvist A., Hovd M., Gandia P., Panchaud A., Guidi M., Annaert P., Baranczewski P., Spigset O. et al., 2025/01. Basic & clinical pharmacology & toxicology, 136 (1) pp. e14100. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A52B902F4CE9]
2024
 
State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case.
Petermann Y.J., Said B., Cathignol A.E., Sariko M.L., Thoma Y., Mpagama S.G., Csajka C., Guidi M., 2024/12. JAC-antimicrobial resistance, 6 (6) pp. dlae182. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CCFBA0899F39]
A population pharmacokinetic model for sertraline in women during the perinatal period-A contribution from the ConcePTION project.
Monfort A., Cardoso E., Eap C.B., Ansermot N., Crettol S., Fischer Fumeaux C.J., Graz M.B., Harari M.M., Weisskopf E., Gandia P. et al., 2024/11. British journal of clinical pharmacology, 90 (11) pp. 2849-2860. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_09F8B14E5C96]
Toward a Clinical Decision Support System for Monitoring Therapeutic Antituberculosis Medical Drugs in Tanzania (Project TuberXpert): Protocol for an Algorithm' Development and Implementation.
Thoma Y., Cathignol A.E., Pétermann Y.J., Sariko M.L., Said B., Csajka C., Guidi M., Mpagama S.G., 2024/10/21. JMIR research protocols, 13 pp. e58720. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B03605089A55]
Novel Patient-Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use.
Dao K., Buettcher M., Golhen K., Kost J., Schittny A., Duthaler U., Atkinson A., Haefliger D., Guidi M., Bardinet C. et al., 2024/10. Journal of clinical pharmacology, 64 (10) pp. 1295-1303. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6FBF4894C204]
 
Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study.
Ravix A., Bandiera C., Cardoso E., Lata-Pedreira A., Chtioui H., Decosterd L.A., Wagner A.D., Schneider M.P., Csajka C., Guidi M., 2024/06/11. Cancers, 16 (12). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3DC9393D4173]
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
Thoueille P., Saldanha S.A., Schaller F., Choong E., Veuve F., Munting A., Cavassini M., Braun D., Günthard H.F., Duran Ramirez J.J. et al., 2024/06. Clinical pharmacology and therapeutics, 115 (6) pp. 1450-1459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A008171B295E]
Population Pharmacokinetics in Oncology and Its Clinical Applications.
Widmer N., Guidi M., Buclin T., 2024/05/25. Pharmaceutics, 16 (6) p. 711. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7F7890B07A5F]
Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS).
Couchepin J., Reinhold I., Kronig I., Guidi M., Buclin T., Schreiber P.W., Neofytos D., Lamoth F., Fungal Infection Network of Switzerland (FUNGINOS), 2024/05. Open forum infectious diseases, 11 (5) pp. ofae223. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7689B1E13106]
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update.
Briki M., Murisier A., Guidi M., Seydoux C., Buclin T., Marzolini C., Girardin F.R., Thoma Y., Carrara S., Choong E. et al., 2024/04/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1236 p. 124039. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC804B352E24]
Population pharmacokinetic analysis of doravirine in real-world people with HIV.
Thoueille P., Delarive L., Cavassini M., Buclin T., Decosterd L.A., Marzolini C., Girardin F.R., Guidi M., Swiss HIV Cohort Study, 2024/04. British journal of clinical pharmacology, 90 (4) pp. 1058-1065. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0E37EFB8FE58]
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures.
Thoueille P., Cavassini M., Guidi M., Buclin T., Girardin F.R., Decosterd L.A., Marzolini C., 2024/02. Open forum infectious diseases, 11 (2) pp. ofae023. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E70DD8E56C37]
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.
Thoueille P., Saldanha S.A., Schaller F., Choong E., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B. et al., 2024/01. The Lancet regional health. Europe, 36 p. 100793. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EE4919775F0F]
2023
 
Évaluation des risques liés aux médicaments pendant l’allaitement [Risk assessment of drugs during breastfeeding]
Cardoso E., Monfort A., Ferreira E., Fischer Fumeaux C.J., Henriot I., Winterfeld U., Gandia P., Guidi M., Panchaud A., 2023/10/18. Revue medicale suisse, 19 (846) pp. 1940-1947. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_709A7C64E9D4]
Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study.
Gaspar F., Terrier J., Favre S., Gosselin P., Fontana P., Daali Y., Lenoir C., Samer C.F., Rollason V., Reny J.L. et al., 2023/10. CPT, 12 (10) pp. 1541-1552. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2BD727D8058F]
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study.
Thoueille P., Delfraysse M., Andre P., Buclin T., Decosterd L.A., Fedeli C., Ustero P., Calmy A., Guidi M., Swiss HIV Cohort Study, 2023/09/27. BMC pharmacology & toxicology, 24 (1) p. 47. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0252DE874823]
Supplementum 272: Abstracts of the Annual meeting of the Swiss Society of Gastroenterology, the Swiss Society of Visceral Surgery, the Swiss Association for the Study of the Liver and the Swiss Society of Endoscopy Nurses and Associates
Juillerat Pascal, Tachet Jérémie, Mercier Thomas, Versace François, Guidi Monia, Buclin Thierry, Decosterd Laurent, Choong Eva, Girardin François, 2023/09/11., Annual meeting of the Swiss Society of Gastroenterology , the Swiss Society of Visceral Surgery, the Swiss Association for the Study of the Liver, the Swiss Society of Endoscopy Nurses and Associates pp. s3511 dans Swiss Medical Weekly, François. Peer-reviewed, SMW Supporting Association.
[URN][DOI][Pmid][serval:BIB_478A7CAB2010]
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.
Courlet P., Abler D., Guidi M., Girard P., Amato F., Vietti Violi N., Dietz M., Guignard N., Wicky A., Latifyan S. et al., 2023/08. CPT, 12 (8) pp. 1170-1181. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A319336A78BD]
 
A Highly Sensitive HPLC-MS/MS MethodFor Multiplex Analysis Of Janus KinaseInhibitors In Plasma
Tachet J., Mercier T., André P., Guidi M., Buclin T., Decosterd L., Choong E., Girardin F., 2023/07. dans 19th World Congress of Basic and Clinical Pharmacology (WCP), Glasgow, July 2023.
[serval:BIB_D39D174AB865]
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
Thoueille P., Alves Saldanha S., Desfontaine V., Kusejko K., Courlet P., Andre P., Cavassini M., Decosterd L.A., Buclin T., Guidi M. et al., 2023/06/01. The Journal of antimicrobial chemotherapy, 78 (6) pp. 1433-1443. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_449BF24E5A20]
 
A highly sensitive HPLC-MS/MS method for multiplex analysis of janus kinase inhibitors in plasma
Tachet Jérémie, André Pascal, Guidi Monia, Buclin Thierry, Decosterd Laurent Arthur, Choong Eva, Girardin François, 2023/05/10. dans Congrès SSMIG 2023 - 10 au 12 mai 2023.
[serval:BIB_449F9C0F20F5]
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging.
Abler D., Courlet P., Dietz M., Gatta R., Girard P., Munafo A., Wicky A., Jreige M., Guidi M., Latifyan S. et al., 2023/05. JCO clinical cancer informatics, 7 pp. e2200126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_D61806C1E839]
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C., Locatelli I., Courlet P., Cardoso E., Zaman K., Stravodimou A., Dolcan A., Sarivalasis A., Zurcher J.P., Aedo-Lopez V. et al., 2023/01/03. Cancers, 15 (1) p. 316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2263B25B85EB]
From personalized to precision medicine in oncology: A model-based dosing approach to optimize achievement of imatinib target exposure.
Goutelle S., Guidi M., Gotta V., Csajka C., Buclin T., Widmer N., 2023. Pharmaceutics, 15 (4) p. 1081. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_829AAAA406A8]
Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project.
Monfort A., Cardoso E., Eap C.B., Fischer Fumeaux C.J., Graz M.B., Morisod Harari M., Weisskopf E., Gandia P., Allegaert K., Nordeng H. et al., 2023. Frontiers in psychiatry, 14 p. 1167870. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EE8A9936EA15]
 
Maternal drugs and breastfeeding: Risk assessment from pharmacokinetics to safety evidence - A contribution from the ConcePTION project.
Cardoso E., Monfort A., Ferreira E., Nordeng H., Winterfeld U., Allegaert K., Gandia P., Guidi M., Panchaud A., 2023. Therapie, 78 (2) pp. 149-156. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_616A71B2E82E]
Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective.
Briki M., André P., Thoma Y., Widmer N., Wagner A.D., Decosterd L.A., Buclin T., Guidi M., Carrara S., 2023. Pharmaceutics, 15 (4) p. 1283. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A82A8DDE8796]
 
Safety of medicines during breastfeeding - from case report to modeling: a contribution from the ConcePTION project.
Cardoso E., Guidi M., Nauwelaerts N., Nordeng H., Teil M., Allegaert K., Smits A., Gandia P., Edginton A., Ito S. et al., 2023. Expert opinion on drug metabolism & toxicology, 19 (5) pp. 269-283. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FDFE0C5041A6]
2022
Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children.
Goutelle S., Thoma Y., Buffet R., Philippe M., Buclin T., Guidi M., Csajka C., 2022/10/01. Pharmaceutics, 14 (10) p. 2107. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1F77B194CA9D]
 
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.
Rodier T., Puszkiel A., Cardoso E., Balakirouchenane D., Narjoz C., Arrondeau J., Fallet V., Khoudour N., Guidi M., Vidal M. et al., 2022/09/01. Pharmaceutics, 14 (9) p. 1844. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_72EF703BC03A]
Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation.
Terrier J., Gaspar F., Guidi M., Fontana P., Daali Y., Csajka C., Reny J.L., 2022/08. Clinical pharmacology and therapeutics, 112 (2) pp. 353-363. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2F23BCB64F8E]
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
Thoueille P., Alves Saldanha S., Schaller F., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B., Furrer H. et al., 2022/07/29. Pharmaceutics, 14 (8) p. 1588. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EA4A25E4F31E]
Enantiospecific pharmacokinetics of intravenous dexmedetomidine in beagles.
Levionnois O.L., Barbarossa A., Bardhi A., Siegenthaler J., Forss Pleyers T., Guidi M., Spadavecchia C., Raillard M., 2022/07. Journal of veterinary pharmacology and therapeutics, 45 (4) pp. 366-372. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F2C44CF39F4A]
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
Courlet P., Cardoso E., Bandiera C., Stravodimou A., Zurcher J.P., Chtioui H., Locatelli I., Decosterd L.A., Darnaud L., Blanchet B. et al., 2022/06/21. Pharmaceutics, 14 (7) p. 1317. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E7FBC59504B2]
Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.
Courlet P., Buclin T., Biollaz J., Mazzoni I., Rabin O., Guidi M., 2022/04. CPT, 11 (4) pp. 469-481. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F6F9604D8FA0]
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
Dao K., Fuchs A., André P., Giannoni E., Decosterd L.A., Marchetti O., Asner S.A., Pfister M., Widmer N., Buclin T. et al., 2022/02/02. The Journal of Antimicrobial Chemotherapy, 77 (2) pp. 457-465. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6EBEF14704F8]
 
Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations.
Goutelle S., Woillard J.B., Buclin T., Bourguignon L., Yamada W., Csajka C., Neely M., Guidi M., 2022/02. Journal of clinical pharmacology, 62 (2) pp. 158-170. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E083EEFD4CCE]
 
Parametric Approaches in Population Pharmacokinetics.
Guidi M., Csajka C., Buclin T., 2022/02. Journal of clinical pharmacology, 62 (2) pp. 125-141. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AEA287B02AD]
 
Safety, tolerability and pharmacokinetic profile of Macozinone (PBTZ169) formulated as native crystal powder: multiple ascendingdoses, phase-Ib trial in healthy volunteers
Chtioui H., Prod'Hom S., Desfontaine V., André P., Moulfi F., Bardinet C., Abo-Loha C., Tessieras J., Rothuizen L.E., Diezi L. et al., 2022. dans 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) - June 2022 Athens. European Journal of Clinical Pharmacology, 2022, 78: 1-163.
[serval:BIB_F1F116FD908F]
 
Safety, tolerability, pharmacokinetic profile and ex-vivo antitubercular acativity of macozinone formulated as spraydredi dispersion (SDD) versus native crystal powder (NCO?: single ascending doses, randomized, placebo-controlled, cross-ouver phase la trial in healthy volunteers
Rothuizen L.E., Ciullini L., Huser-Pitteloud J., Guidi M., Chtioui H., Ivanyuk A., André P., Bardinet C., Decosterd L.A., Spaggiari D. et al., 2022. dans SGAIM/SSMIG 6th Spring Congress Lausanne, June 2022. Primary and Hospital Care 2022: 22 (Suppl. 12), 173.
[serval:BIB_B502CD64B984]
2021
 
Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial.
Courlet P., Barbieux C., Sculier D., Wandeler G., Stoeckle M., Bernasconi E., Braun D., Vernazza P., Cavassini M., Marinosci A. et al., 2021/11. British journal of clinical pharmacology, 87 (11) pp. 4455-4460. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_87880AB3A5A2]
 
Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors.
Colombo I., Genta S., Martorana F., Guidi M., Frattini M., Samartzis E.P., Brandt S., Gaggetta S., Moser L., Pascale M. et al., 2021/09/15. Clinical cancer research, 27 (18) pp. 5012-5019. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F48454275B82]
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
Courlet P., Guidi M., Alves Saldanha S., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A., Csajka C., 2021/07. European journal of clinical pharmacology, 77 (7) pp. 979-987. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DCBBE5FFBE88]
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Courlet P., Guidi M., Alves Saldanha S., Stader F., Traytel A., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A. et al., 2021/03. Clinical pharmacokinetics, 60 (3) pp. 379-390. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CF76FDD25628]
Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID - imatinib study.
Bartelink I.H., Bet P.M., Widmer N., Guidi M., Duijvelaar E., Grob B., Honeywell R., Evelo A., Tielbeek IPE, Snape S.D. et al., 2021. CPT, 10 (12) pp. 1497-1511. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1F1A8DF39680]
2020
 
A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk.
Weisskopf E., Guidi M., Fischer C.J., Bickle Graz M., Beaufils E., Nguyen K.A., Morisod Harari M., Rouiller S., Rothenburger S., Gaucherand P. et al., 2020/08. British journal of clinical pharmacology, 86 (8) pp. 1642-1653. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6EA0D4637119]
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
Courlet P., Decosterd L.A., Alves Saldanha S., Cavassini M., Stader F., Stoeckle M., Buclin T., Marzolini C., Csajka C., Guidi M. et al., 2020/08. Clinical pharmacokinetics, 59 (8) pp. 1037-1048. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B56252981556]
 
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Cardoso E., Guidi M., Khoudour N., Boudou-Rouquette P., Fabre E., Tlemsani C., Arrondeau J., Goldwasser F., Vidal M., Schneider M.P. et al., 2020/07. Clinical Therapeutics, 42 (7) pp. 1302-1316. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C945C7298567]
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma.
Balakirouchenane D., Guégan S., Csajka C., Jouinot A., Heidelberger V., Puszkiel A., Zehou O., Khoudour N., Courlet P., Kramkimel N. et al., 2020/04/09. Cancers, 12 (4). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E1BBC7ED0901]
Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K., Guidi M., André P., Giannoni E., Basterrechea S., Zhao W., Fuchs A., Pfister M., Buclin T., Csajka C., 2020/04. Pharmacological research, 154 p. 104278. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E0DB9448258C]
Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses.
Glatard A., Guidi M., Delacrétaz A., Dubath C., Grosu C., Laaboub N., von Gunten A., Conus P., Csajka C., Eap C.B., 2020/03. Clinical pharmacokinetics, 59 (3) pp. 371-382. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_750BA5D2C6D5]
Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers.
Dao K., Thoueille P., Decosterd L.A., Mercier T., Guidi M., Bardinet C., Lebon S., Choong E., Castang A., Guittet C. et al., 2020/02. Pharmacology research & perspectives, 8 (1) pp. e00558. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0D0F21F7F1EC]
Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy.
Barceló C., Guidi M., Thorball C.W., Hammer C., Chaouch A., Scherrer A.U., Hasse B., Cavassini M., Furrer H., Calmy A. et al., 2020/01. Open forum infectious diseases, 7 (1) pp. ofz464. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7951F9D906D0]
 
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P., Stader F., Guidi M., Alves Saldanha S., Stoeckle M., Cavassini M., Battegay M., Buclin T., Decosterd L.A., Marzolini C. et al., 2020/01/01. AIDS, 34 (1) pp. 103-108. Peer-reviewed.
[DOI][Pmid][serval:BIB_B80C7E3E1838]
The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib
Buclin T., Thoma Y., Widmer N., André P., Guidi M., Csajka C., Decosterd L..A., 2020. Frontiers in Pharmacology, 11 p. 177. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_9A25C1CC37D8]
 
Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review.
Cardoso E., Guidi M., Blanchet B., Schneider M.P., Decosterd L.A., Buclin T., Csajka C., Widmer N., 2020. Therapeutic Drug Monitoring, 42 (1) pp. 33-44. Peer-reviewed.
[DOI][Pmid][serval:BIB_2BF80A005C57]
2019
Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV.
Courlet P., Livio F., Guidi M., Cavassini M., Battegay M., Stoeckle M., Buclin T., Alves Saldanha S., Csajka C., Marzolini C. et al., 2019/12. Open forum infectious diseases, 6 (12) pp. ofz531. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_747A12E6A2E6]
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/09. British journal of clinical pharmacology, 85 (9) pp. 2022-2032. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F5C6318349C9]
 
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C., Aouri M., Courlet P., Guidi M., Braun D.L., Günthard H.F., Piso R.J., Cavassini M., Buclin T., Decosterd L.A. et al., 2019/09/01. The Journal of antimicrobial chemotherapy, 74 (9) pp. 2690-2697. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_525CE7DE74FD]
Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population.
Glatard A., Guidi M., Dobrinas M., Cornuz J., Csajka C., Eap C.B., 2019/07. European journal of clinical pharmacology, 75 (7) pp. 939-949. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1B9CBBB244BC]
Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Guidi M., Mercier T., Aouri M., Decosterd L.A., Csajka C., Ogutu B., Carn G., Kiechel J.R., 2019/04/18. Malaria journal, 18 (1) p. 139. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BBD62F6B6F27]
Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial.
Sottas O., Guidi M., Thieffry B., Schneider M., Décosterd L., Mueller I., Genton B., Csajka C., Senn N., 2019. PloS one, 14 (2) pp. e0210789. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A2EC9261874C]
2018
 
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R., Guidi M., Calpini V., Lamoth F., Decosterd L., Robatel C., Buclin T., Csajka C., Marchetti O., 2018/12/01. The Journal of antimicrobial chemotherapy, 73 (12) pp. 3413-3422. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C826664F7442]
 
Robustness analysis of personalised delivery rate computation for IV administered anesthetic
Simalatsar Alena, Guidi Monia, Roduit Pierre, Buclin Thierry, 2018/12. Smart Health, 9-10 pp. 101-114.
[DOI][serval:BIB_97D4311206EF]
 
Methods for Personalised Delivery Rate Computation for Propofol IV Administered Anesthetic
Simalatsar Alena, Guidi Monia, Roduit Pierre, Buclin Thierry, 2018. dans Automated Reasoning for System Biology and Medicine, Springer International Publishing.
[serval:BIB_9EB3302639F8]
2017
 
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M., Barcelo C., Guidi M., Rotger M., Cavassini M., Hizrel C., Buclin T., Decosterd L.A., Csajka C., Swiss HIV Cohort Study, 2017/04. Antimicrobial agents and chemotherapy, 61 (1) p. 10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_551E69A36AD5]
 
The levels of vancomycin in the blood and the wound after the local treatment of bone and soft-tissue infection with antibiotic-loaded calcium sulphate as carrier material.
Wahl P., Guidi M., Benninger E., Rönn K., Gautier E., Buclin T., Magnin J.L., Livio F., 2017. The Bone & Joint Journal, 99-B (11) pp. 1537-1544. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A8C52B738E32]
2016
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.
Csajka C., Crettol S., Guidi M., Eap C.B., 2016/12. Clinical pharmacokinetics, 55 (12) pp. 1521-1533. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_038FD2A79BD0]
 
Cascaded PID controller for anaesthesia delivery.
Simalatsar A., Guidi M., Buclin T., 2016/08. Conference proceedings, 2016 pp. 533-536. Peer-reviewed.
[DOI][Pmid][serval:BIB_2E02DD33E302]
 
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C., Gaspar F., Aouri M., Panchaud A., Rotger M., Guidi M., Cavassini M., Buclin T., Decosterd L.A., Csajka C. et al., 2016/07. The Journal of antimicrobial chemotherapy, 71 (7) pp. 1933-1942. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_001364580150]
2015
 
Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry.
Guidi M., Foletti G., McLaren P., Cavassini M., Rauch A., Tarr P.E., Lamy O., Panchaud A., Telenti A., Csajka C. et al., 2015/07. Antiviral Therapy, 20 (3) pp. 261-269. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_60B0877DA09D]
 
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Petit-Jean E., Buclin T., Guidi M., Quoix E., Gourieux B., Decosterd L.A., Gairard-Dory A.C., Ubeaud-Séquier G., Widmer N., 2015. Therapeutic Drug Monitoring, 37 (1) pp. 2-21. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1E06AAEC7E81]
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
Vandenberghe F., Guidi M., Choong E., von Gunten A., Conus P., Csajka C., Eap C.B., 2015. Clinical Pharmacokinetics, 54 (12) pp. 1259-1272. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_594496D78157]
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. pp. Abstr. 3505 dans 24th Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[serval:BIB_08604FD033C0]
2014
 
Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.
Mosha D., Guidi M., Mwingira F., Abdulla S., Mercier T., Decosterd L.A., Csajka C., Genton B., 2014/08. Antimicrobial Agents and Chemotherapy, 58 (8) pp. 4583-4592. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2037BBD1EF7C]
 
High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.
Mercier T., Tissot F., Gardiol C., Corti N., Wehrli S., Guidi M., Csajka C., Buclin T., Couet W., Marchetti O. et al., 2014. Journal of Chromatography. A, 1369 pp. 52-63. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0D0099C7E204]
 
Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique [Pharmacokinetic Alterations in Pregnancy and Use of Therapeutic Drug Monitoring].
Panchaud A., Weisskopf E., Winterfeld U., Baud D., Guidi M., Eap C.B., Csajka C., Widmer N., 2014. Therapie, 69 (3) pp. 223-234. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_18592A49D874]
 
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Stancu I., Alnawaqil A.M., Bula C. et al., 2014. British Journal of Clinical Pharmacology, 78 (1) pp. 135-144. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D0309E8CA034]
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M., Lubomirov R., Fayet-Mello A., Aouri M., Rotger M., Buclin T., Widmer N., Gatri M., Ledergerber B., Rentsch K. et al., 2014. Journal of Antimicrobial Chemotherapy, 69 (9) pp. 2489-2498. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1E8FAB4C9089]
 
Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.
Fuchs A., Guidi M., Giannoni E., Werner D., Buclin T., Widmer N., Csajka C., 2014. British Journal of Clinical Pharmacology, 78 (5) pp. 1090-1101. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_44A869ECA1E5]
2013
 
Population pharmacokinetic study of memantine: effects of clinical and genetic factors.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Alnawaqil A.M., Maurer S., Zumbach S. et al., 2013/03. Clinical pharmacokinetics, 52 (3) pp. 211-223. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6598521C6000]
 
Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.
Staehli Hodel E.M., Csajka C., Ariey F., Guidi M., Kabanywanyi A.M., Duong S., Decosterd L.A., Olliaro P., Beck H.P., Genton B., 2013. Antimicrobial Agents and Chemotherapy, 57 (2) pp. 950-958.
[DOI][WoS][Pmid][serval:BIB_0195967C8F4F]
 
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R., Arab-Alameddine M., Rotger M., Fayet-Mello A., Martinez R., Guidi M., di Iulio J., Cavassini M., Günthard H.F., Furrer H. et al., 2013. Pharmacogenetics and Genomics, 23 (1) pp. 9-18. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CDA03D8C1D2B]
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Staehli Hodel E.M., Guidi M., Zanolari B., Mercier T., Duong S., Kabanywanyi A.M., Ariey F., Buclin T., Beck H.P., Decosterd L.A. et al., 2013. Malaria Journal, 12 p. 235. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_35BEA32B625E]
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF51D91AAB14]
 
Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations.
Noetzli M., Guidi M., Ebbing K., Eyer S., Zumbach S., Giannakopoulos P., von Gunten A., Csajka C., Eap C.B., 2013. Therapeutic Drug Monitoring, 35 (2) pp. 270-275. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A5DFF6BBD3DF]
2012
 
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Guidi M., Arab-Alameddine M., Rotger M., Aouri M., Telenti A., Decosterd L.A., Buclin T., Csajka C., Swiss HIV Cohort Study, 2012. Chimia, 66 (5) pp. 291-295. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C4CE4C9D2166]
2009
 
Spectroscopy of protonated peptides assisted by infrared multiple photon excitation.
Guidi M., Lorenz U.J., Papadopoulos G., Boyarkin O.V., Rizzo T.R., 2009/02/05. The journal of physical chemistry. A, 113 (5) pp. 797-799. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_28F7B71C2C75]
2007
 
Conformation-specific infrared and ultraviolet spectroscopy of tyrosine-based protonated dipeptides.
Stearns J.A., Guidi M., Boyarkin O.V., Rizzo T.R., 2007/10/21. The Journal of chemical physics, 127 (15) p. 154322. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9F6052164E85]
 
Conformation-specific spectroscopy and photodissociation of cold, protonated tyrosine and phenylalanine.
Stearns J.A., Mercier S., Seaiby C., Guidi M., Boyarkin O.V., Rizzo T.R., 2007/09/26. Journal of the American Chemical Society, 129 (38) pp. 11814-11820. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7183D52C78C2]
 
Some properties of lysozyme--lithium perfluorononanoate complexes.
Ciurleo A., Cinelli S., Guidi M., Bonincontro A., Onori G., Mesa C.L., 2007/02. Biomacromolecules, 8 (2) pp. 399-405. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_682343D08A56]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University